Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-945429 dose-ranging induction and maintenance study in moderate to severe Crohn's disease
NL-OMON37627Phase 2Withdrawn
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing BMS-945429 with Placebo (2 arms). Primary endpoint: Clinical remission at Week 8. Planned start Jun 2012; status: withdrawn.
02
Drugs
clazakizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON37627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37627.